Article
Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.
Oncology research and treatment - 1 Jan 2016
Moiseyenko Fedor V, Moiseyenko Vladimir M, Aleksakhina Svetlana N, Chubenko Vyacheslav A, Volkov Nikita M, Kozyreva Kseniya S, Kramchaninov Michail M, Zhuravlev Alexandr S, Shelekhova Kseniya V, Ivantsov Alexandr O, Venina Aigul R, Preobrazhenskaya Elena V, Mitiushkina Natalia V, Iyevleva Aglaya G, Imyanitov Evgeny N
Abstract excerpt
BACKGROUND: Discontinuation of gefitinib treatment is often accompanied by a disease flare. Some studies have demonstrated a benefit of the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) beyond progression; however, long-term results of these investigations remain limited. PATIENTS AND METHODS: We observed 70 patients with EGFR-mutated (EGFR-M+) non-small cell lung cancer (NSCLC)...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Disease Progression
- Disease-Free Survival
- ErbB Receptors
- Female